Cerveau Technologies, Inc. has entered into license agreement with Merck & Co., Inc. for the global development and commercialization of Merck's early stage investigational imaging agent (MK-6240) being evaluated for use in positron emission tomography (PET) scans to image neurofibrillary tangles (NFTs) in the brain. Both the companies are based in the US. NFTs made up of aggregated tau protein are a hallmark of several neurodegenerative diseases, including Alzheimer's disease. As part of the agreement, Cerveau will be responsible for the clinical development and commercialization of MK-6240 in return for payment of license fees, milestone payments and royalties on worldwide sales of any future marketed products. Cerveau plans to initiate a phase III clinical program in early 2018.